Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
69,070.89 +366.41 (+0.53%) CMC Crypto 200
1,447.50 -20.60 (-1.40%)
REGN Jun 2024 885.000 put
| Previous close | 2.3200 |
| Open | 2.3200 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 885.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.3200 - 2.3200 |
| Contract range | N/A |
| Volume | |
| Open interest | 116 |
Insider MonkeyThe Biggest Publicly Traded Biotech Company
In this article, we will be discussing the biggest publicly traded biotech company that ranks at the top of our free list of the 20 Biggest Publicly Traded Biotech Companies. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate […]
ZacksRegeneron (REGN) Announces Positive Data on Oncology Candidate
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
GlobeNewswirePromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors TARRYTOWN, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results
